Key result
Lipid accumulation product best predicts metabolic syndrome in CKD, achieving an AUC up to ~0.91.
Why the study?
The ability of lipid accumulation product and visceral adiposity index to predict metabolic syndrome in chronic kidney disease patients and their superiority to traditional body indices was unclear.
Do lipid accumulation product (LAP) and visceral adiposity index (VAI) predict metabolic syndrome better than traditional body indices in patients with chronic kidney disease?
Observational (n=247)
Do lipid accumulation product (LAP) and visceral adiposity index (VAI) predict metabolic syndrome better than traditional body indices in patients with chronic kidney disease?
Effect estimate: AUC 0.864 in females and 0.908 in males for LAP
LAP and VAI are effective and superior indices for predicting metabolic syndrome in patients with stage 3-5 chronic kidney disease.
LAP may aid metabolic syndrome screening in CKD; hypothesis-generating and requires prospective validation before practice change.
OBJECTIVE: The aim of this study was to assess the ability of lipid accumulation product (LAP) and visceral adiposity index (VAI) to predict metabolic syndrome (MetS) in patients with chronic kidney disease (CKD). We also aimed to determine whether VAI and LAP indices are superior to traditional body indices such as body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR). PATIENTS AND METHODS: This study was performed by retrospectively scanning the files of patients with stage 3-5 chronic renal failure who came for nephrology outpatient follow-up between January 2017 and December 2017. Metabolic syndrome was identified using the 2009 harmonized criteria. The receiver operating characteristic curve (ROC) was used to compare the area under the ROC curve (AUC) of each index. RESULTS: 247 patients were included in the analyses. The prevalence of MetS was 80.9%. LAP was determined as the optimal predictor in chronic kidney disease patients, with 0.864 AUC in females and 0.908 AUC in males. Optimal cut-off values for LAP were 33.5 in females and 36.6 in males. VAI was the second most optimal predictor, with 0.856 AUC in females and 0.888 AUC in males. Optimal cut-off values for VAI were 2.24 in females and 1.56 in males. CONCLUSIONS: LAP and VAI are effective indices for the prediction of MetS in patients with chronic kidney disease; LAP is the best index for the determination of MetS in both men and women.
No takes yet. Share an insight, caveat, or question.
Bıyık et al. (2019) conducted an observational in Chronic kidney disease (n=247). Lipid accumulation product (LAP) and visceral adiposity index (VAI) vs. Traditional body indices (BMI, WC, WHR, WHtR) was evaluated on Prediction of metabolic syndrome (MetS) (AUC 0.864 in females and 0.908 in males for LAP). Lipid accumulation product (LAP) was the optimal predictor of metabolic syndrome in patients with chronic kidney disease, achieving an AUC of 0.864 in females and 0.908 in males.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: